Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
作者信息
Taneja Alankrita, Jones Jade, Pittaluga Stefania, Maric Irina, Farooqui Mohammed, Ahn Inhye E, Wiestner Adrian, Sun Clare
机构信息
a Hematology Branch , National Heart, Lung, and Blood Institute, National Institutes of Health , Bethesda , MD , USA.
b Division of Cancer Medicine , MD Anderson Cancer Center , Houston , TX , USA.
出版信息
Leuk Lymphoma. 2019 Feb;60(2):519-522. doi: 10.1080/10428194.2018.1480775. Epub 2018 Jul 6.
Abstract
摘要
相似文献
1
Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.在布鲁顿酪氨酸激酶抑制剂治疗期间转化为霍奇金淋巴瘤的 Richter 转化
Leuk Lymphoma. 2019 Feb;60(2):519-522. doi: 10.1080/10428194.2018.1480775. Epub 2018 Jul 6.
2
BTK/PD-1 blockade for treatment of Richter's transformation.布鲁顿酪氨酸激酶/程序性死亡受体1阻断疗法用于治疗里氏转化。
Lancet Haematol. 2019 Feb;6(2):e59-e60. doi: 10.1016/S2352-3026(18)30219-9. Epub 2019 Jan 11.
3
Targeting Bruton's Tyrosine Kinase in CLL.针对慢性淋巴细胞白血病中的布鲁顿酪氨酸激酶。
Front Immunol. 2021 Jun 23;12:687458. doi: 10.3389/fimmu.2021.687458. eCollection 2021.
4
Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.伊布替尼治疗慢性淋巴细胞白血病过程中出现布鲁顿酪氨酸激酶阴性霍奇金淋巴瘤。
Eur J Haematol. 2017 Oct;99(4):378-380. doi: 10.1111/ejh.12911. Epub 2017 Jul 5.
5
Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.泽布替尼：一种用于慢性淋巴细胞白血病和非霍奇金淋巴瘤的新型布鲁顿酪氨酸激酶抑制剂。
Clin Adv Hematol Oncol. 2019 Jan;17(1):32-34.
6
Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.慢性淋巴细胞白血病/小淋巴细胞白血病管理的长期随访和未来方向。
J Oncol Pharm Pract. 2022 Dec;28(8):1869-1884. doi: 10.1177/10781552221103820. Epub 2022 May 30.
7
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶抑制剂可抑制慢性淋巴细胞白血病中 FcγRIIA 介导的血小板对细菌的反应。
Front Immunol. 2021 Nov 29;12:766272. doi: 10.3389/fimmu.2021.766272. eCollection 2021.
8
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.泽布替尼治疗复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的疗效：一项 2 期、单臂、多中心研究。
J Hematol Oncol. 2020 May 11;13(1):48. doi: 10.1186/s13045-020-00884-4.
9
Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.布鲁顿酪氨酸激酶抑制剂依鲁替尼对既往治疗过的华氏巨球蛋白血症的长期随访
Leuk Lymphoma. 2017 Jun;58(6):1502-1505. doi: 10.1080/10428194.2016.1247957. Epub 2016 Oct 26.
10
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.泽布替尼对慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者免疫细胞的影响。
Hematol Oncol. 2019 Oct;37(4):392-400. doi: 10.1002/hon.2667. Epub 2019 Sep 13.
引用本文的文献
1
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.B 细胞受体通路突变在连续伊布替尼治疗的慢性淋巴细胞白血病患者中罕见。
Clin Cancer Res. 2023 Aug 15;29(16):3065-3073. doi: 10.1158/1078-0432.CCR-22-3887.
2
Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.伊布替尼初治时慢性淋巴细胞白血病患者未化疗即早期转化为经典型霍奇金淋巴瘤。
Intern Med. 2021 Oct 15;60(20):3305-3308. doi: 10.2169/internalmedicine.6979-20. Epub 2021 Apr 26.
3
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.在接受 BTK 抑制剂阿卡替尼治疗的 CLL 中，靶标占有率的临床和生物学意义。
Blood. 2020 Jul 2;136(1):93-105. doi: 10.1182/blood.2019003715.
本文引用的文献
1
Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia.依鲁替尼治疗复发慢性淋巴细胞白血病后发生的 Richter 综合征的临床、病理及生物学特征
Hematol Oncol. 2018 Feb 27. doi: 10.1002/hon.2502.
2
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.616 例美国伊布替尼治疗患者的毒性和结局：真实世界分析。
Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.
3
Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant.异基因造血干细胞移植后慢性淋巴细胞白血病患者使用依鲁替尼成功治疗Richter转化
Case Rep Oncol. 2017 Jun 19;10(2):534-541. doi: 10.1159/000477338. eCollection 2017 May-Aug.
4
Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.伊布替尼治疗慢性淋巴细胞白血病过程中出现布鲁顿酪氨酸激酶阴性霍奇金淋巴瘤。
Eur J Haematol. 2017 Oct;99(4):378-380. doi: 10.1111/ejh.12911. Epub 2017 Jul 5.
5
Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?依鲁替尼治疗下慢性淋巴细胞白血病转化为霍奇金淋巴瘤：偶然关联还是与治疗相关？
Anticancer Res. 2017 Jun;37(6):3277-3280. doi: 10.21873/anticanres.11692.
6
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.依鲁替尼治疗后慢性淋巴细胞白血病进展的临床病理特征和结局。
Blood. 2017 Jun 22;129(25):3362-3370. doi: 10.1182/blood-2017-01-763003. Epub 2017 May 4.
7
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.维奈托克在复发或难治性非霍奇金淋巴瘤患者中的I期首次人体研究。
J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.
8
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.导致慢性淋巴细胞白血病对伊布替尼耐药的克隆进化。
Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.
9
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).肿瘤对激酶抑制剂的耐药性之谜与癌症耐药性指数（DRIC）的计算。
Semin Cancer Biol. 2017 Aug;45:36-49. doi: 10.1016/j.semcancer.2016.11.008. Epub 2016 Nov 16.
10
Ibrutinib in Refractory Classic Hodgkin's Lymphoma.伊布替尼治疗难治性经典型霍奇金淋巴瘤
N Engl J Med. 2015 Oct;373(14):1381-2. doi: 10.1056/NEJMc1505857.
Zotero 插件